Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone44-0-12-3544-3939
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$36.07 million
Profitability
Miscellaneous
Employees60
OptionableOptionable
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) posted its quarterly earnings data on Tuesday, June, 5th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.21. The company earned $5.33 million during the quarter, compared to analyst estimates of $6.48 million. SUMMIT THERAPEU/S had a net margin of 0.37% and a return on equity of 1.16%. View SUMMIT THERAPEU/S's Earnings History.
When is SUMMIT THERAPEU/S's next earnings date?
What price target have analysts set for SMMT?
9 brokers have issued 1 year target prices for SUMMIT THERAPEU/S's shares. Their forecasts range from $3.00 to $33.00. On average, they anticipate SUMMIT THERAPEU/S's stock price to reach $14.7143 in the next year. This suggests a possible upside of 894.2% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.
What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.
Has SUMMIT THERAPEU/S been receiving favorable news coverage?
Media headlines about SMMT stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SUMMIT THERAPEU/S earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include Medicure (MCUJF), Entasis Therapeutics (ETTX), Aridis Pharmaceuticals (ARDS), Elite Pharmaceuticals (ELTP), CTI BioPharma (CTIC), Infinity Pharmaceuticals (INFI), Avenue Therapeutics (ATXI), KemPharm (KMPH), Synergy Pharmaceuticals (SGYP), Tetraphase Pharmaceuticals (TTPH), Zynerba Pharmaceuticals (ZYNE), Immune Design (IMDZ), Merrimack Pharmaceuticals (MACK), Scpharmaceuticals (SCPH) and Fortress Biotech (FBIO).
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
- Ms. Michelle Avery, Director of Investor Relations
- Richard Pye, Sr. Director of Corp. Affairs & Communications
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $1.48.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $20.48 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 60 workers across the globe.
What is SUMMIT THERAPEU/S's official website?
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-0-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
